Talk:BeiGene

Page contents not supported in other languages.
Source: Wikipedia, the free encyclopedia.

Intro and History sections

Thanks in advance for helping me out with this edit request to the Introduction and History sections of the article.

  1. Please add the word "global" to the first sentence so that it reads: "BeiGene is a global biotechnology company…" [1]
  2. There is no reliable source that supports the claim in the second sentence of the Intro that the company was founded in Beijing. Please remove the words "in Beijing" from that sentence so it says instead: "Founded in 2010 by Xiaodong Wang…"
  3. Also in the second sentence, but at the end, there is a list of office locations. For consistency, please remove the countries listed and switch them out for continents, so instead the list says: "…the company has offices in Asia, North America, Australia and Europe."
  4. Please remove the last part of the last sentence. That clause is too much detail for the introduction, and is already stated in the "Research and development section." The part to be removed is "a Bruton's tyrosine kinase inhibitor that became the first cancer drug developed in China to gain the U.S. Food and Drug Administration's approval when it received accelerated approval to treat mantle cell lymphoma in November 2019."
  5. In the History section, after the first sentence, please add the following sentence and source:
As of early 2023, the company had more than 9,000 employees worldwide.[2]

References

  1. ^ Liu, Angus (29 April 2022). "BeiGene CEO touts 'strategic asset' in flagship US site and a fix to stock delisting risk". FiercePharma.
  2. ^ "BeiGene, Ltd. (BGNE)". Yahoo! Finance. 17 February 2023.

Thanks again for all your help, LexBGNE (talk) 20:15, 28 February 2023 (UTC)[reply]

Done. Spotted your request on Athel cb's talk page. U003F? 06:51, 5 May 2023 (UTC)[reply]
U003F, thank you for your help! LexBGNE (talk) 18:30, 11 May 2023 (UTC)[reply]

COI edit requests

Hi! BeiGene is a client of my employer, Porter Novelli. Requesting some updates to this article. I've also mocked up the changes here.

  • I noticed this article has recently been moved from
    MOS:CAMELCASE
    , I suggest that this change be reverted, given that the vast majority of media coverage capitalizes the G in the name.
  • Once the below has been reviewed, I'd love to revisit what else might be necessary to address the {{advert}} flag on this article.
  • Update the {{Short description}} to "Global biotechnology company", per the article lead.

History

  • Update, per the cited source:
As of early 2023, the company had more than 9,000 employees worldwide.[1]
to
As of early 2023, the company had more than 9,400 employees worldwide.[2]
  • Delete
While many pharmaceutical drugs are manufactured in China, almost all early research and development for the drugs takes place elsewhere.
The closest citations in the text are [3] and [4], but neither ref substantiates the information.
  • Update with more neutral/condensed language:
Wang and Oyler envisioned a
cancer treatment.[3]
to
Wang and Oyler envisioned a
cancer treatment.[3]
By July 2011, they had recruited more than 60 Chinese scientists, including 20 who were U.S.-educated.
to
By July 2011, they had recruited 60 scientists, including 20 who were Chinese-born and U.S.-educated or had worked at an American or European pharmaceutical company.
  • Update
In the US, Beigene has offices in California, Massachusetts, and New Jersey.[7]
to
In the U.S., BeiGene has offices in California, Maryland,[8] Massachusetts, and New Jersey.[9]
  • Add to end of section:
In November 2018, BeiGene began a license and collaboration agreement with biotech company Zymeworks.[10] In December 2021, the two companies began a phase 3 clinical trial of zanidatamab, a bispecific antibody.[11]
In November 2022, the company began offering a program to help patients better manage mental health issues associated with cancer, called "Talk About It".[12][13] BeiGene also partnered with the Cancer Support Community to conduct additional research on cancer and mental health.[14]

Research and development

  • Delete
In addition to clinical research, BeiGene's early business model involved obtaining the rights to experimental medicines shelved by other pharmaceutical companies and taking them through early clinical trials at Chinese medical schools and hospitals. Successful formulas would either be sold to or co-developed with larger drugmakers who could fund the late-stage trials.[3]
The cited source states this speculatively: "BeiGene hopes to buy..."; "Those that are successful may be sold back". Per
WP:CRYSTALBALL
, I believe it makes sense to remove this.
  • Break this section into two subsections: "Tislelizumab" (the second paragraph, now the first if the above is implemented) and "Zanubrutinib" (currently the final paragraph).
  • Delete "in both directions" – feels like odd wording.
  • A couple tense/framing updates in the second paragraph to reflect the drug's current status:
    • Update "One of BeiGene's late-stage therapies" to "One of BeiGene's internally developed medicines"
    • Update "Tislelizumab is being developed as a monotherapy and in combination" to "Tislelizumab was developed as a monotherapy and for use in combination"
  • Add (CLL) after the first mention of chronic lymphocytic leukemia and (SLL) after the first mention of small lymphocytic lymphoma.
  • Add to end of third paragraph:
Zanubrutinib was approved for treatment of adult patients with CLL and SLL by the European Commission in November 2022[15][16] and by the FDA in January 2023.[17]
  • Add new subsection:
=== Pamiparib ===
Pamiparib (Partruvix) is a selective poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) inhibitor developed by BeiGene.[18][19] It has been approved in China for the treatment of BRCA recurrent advanced ovarian, fallopian tube or primary peritoneal cancer.[18]


Sources

  1. ^ "BeiGene, Ltd. (BGNE)". Yahoo! Finance. 17 February 2023.
  2. ^ "BeiGene, Ltd. (BGNE)". Yahoo! Finance. 17 February 2023.
  3. ^ a b c d e f g Loo, Daryl (2011-07-07). "BeiGene Brings Biotech to China". Bloomberg. Retrieved 2020-08-04.
  4. ^ Wright, Rob (2019-11-01). "How — And Why — John Oyler Built BeiGene". Life Science Leader. Retrieved 2020-08-04.
  5. ^ Wright, Rob (2019-11-01). "How — And Why — John Oyler Built BeiGene". Life Science Leader. Retrieved 2020-08-04.
  6. ^ Wright, Rob (2019-11-01). "How — And Why — John Oyler Built BeiGene". Life Science Leader. Retrieved 2020-08-04.
  7. ISSN 0099-9660
    . Retrieved 2020-08-04.
  8. ^ Liu, Angus (29 April 2022). "BeiGene CEO touts 'strategic asset' in flagship US site and a fix to stock delisting risk". Fierce Pharma. Retrieved 30 June 2023.
  9. ISSN 0099-9660
    . Retrieved 2020-08-04.
  10. ^ Taylor, Nick Paul (27 November 2018). "BeiGene bags Asian rights to Zymeworks' HER2 bispecifics". Fierce Biotech. Retrieved 30 June 2023.
  11. ^ Buntz, Brian (9 December 2021). "Zymeworks and its partner BeiGene expand zanidatamab pivotal trial in Asia". Drug Discovery and Development. Retrieved 30 June 2023.
  12. ^ Adams, Ben (17 November 2022). "BeiGene delves into cancer care's mental health impact, launching 'Talk About It' to treat patients beyond their disease". Fierce Pharma. Retrieved 30 June 2023.
  13. ^ Renfrow, Jacqueline (10 February 2023). "BeiGene boosts mental health resources for cancer patients as it doubles down on 'Talk About It' campaign". Fierce Pharma. Retrieved 30 June 2023.
  14. ^ Snyder Bulik, Beth (3 February 2023). "BeiGene reveals mental health and cancer care gap in study, debuts digital resources". Endpoints News. Retrieved 30 June 2023.
  15. ^ "BeiGene's Brukinsa receives EC approval for chronic lymphocytic leukaemia". PMLive. 21 November 2022. Retrieved 30 June 2023.
  16. ^ Liu, Angus (22 November 2022). "ASH: AbbVie, J&J's Imbruvica under serious threat as BeiGene's Brukinsa delivers head-to-head trial win". Fierce Pharma. Retrieved 30 June 2023.
  17. ^ Killmurray, Conor (19 January 2023). "FDA Approves Zanubrutinib in Adult Patients with CLL/SLL". Targeted Oncology. Retrieved 30 June 2023.
  18. ^ a b Carvalho, Joana (23 July 2020). "Pamiparib Under Review in China to Treat Advanced Ovarian Cancer". Ovarian Cancer News Today. Retrieved 30 June 2023.
  19. ^ Adams, Ben (19 August 2022). "Chinese biopharma BeiGene teams with real-world evidence data firm Ontada to campaign for better cancer drug access in the US". Fierce Pharma. Retrieved 30 June 2023.

Thank you for your time and feedback! Mary Gaulke (talk) 19:30, 12 July 2023 (UTC)[reply]

WP:CRYSTAL pertains to text in Wikipedia, not to how text is worded in sources. Also, please provide the WikiLinks for Tislelizumab, Pamiparib, CLL and SLL so that they may be incorporated into the article. The term "in both directions", it's not clear from your request where this is located in the article. Please advise. Regards  Spintendo  15:29, 13 July 2023 (UTC)[reply
]
Thanks for the quick reply!
small lymphocytic lymphoma redirects to the same. Looks like the "in both directions" phrase was deleted from the article recently – I'll strike it out above. Thanks again. Mary Gaulke (talk) 22:07, 13 July 2023 (UTC)[reply
]

Reply 13-JUL-2023

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.  Spintendo  23:17, 13 July 2023 (UTC)[reply]

Edit request review 13-JUL-2023

As of early 2023, the company had more than 9,400 employees worldwide.
 Approved.[note 1]


While many pharmaceutical drugs are manufactured in China, almost all early research and development for the drugs takes place elsewhere.
Clarification needed.[note 2]


Wang and Oyler envisioned a biopharmaceutical company with research and development in China, focusing on cancer treatment.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


By July 2011, they had recruited 60 scientists, including 20 who were Chinese-born and U.S.-educated or had worked at an American or European pharmaceutical company.
no Declined.[note 3]


In the U.S., BeiGene has offices in California, Maryland, Massachusetts, and New Jersey
no Declined.[note 4]


In November 2018, BeiGene began a license and collaboration agreement with biotech company Zymeworks. In December 2021, the two companies began a phase 3 clinical trial of zanidatamab, a bispecific antibody.
Clarification needed.[note 5]


In November 2022, the company began offering a program to help patients better manage mental health issues associated with cancer, called "Talk About It". BeiGene also partnered with the Cancer Support Community to conduct additional research on cancer and mental health.
no Declined.[note 6]


Update "One of BeiGene's late-stage therapies" to "One of BeiGene's internally developed medicines"
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


"Tislelizumab was developed as a monotherapy and for use in combination"
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


Add to end of third paragraph: Zanubrutinib was approved for treatment of adult patients with CLL and SLL by the European Commission in November 2022 and by the FDA in January 2023.
Clarification needed.[note 7]


Pamiparib (Partruvix) is a selective poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) inhibitor developed by BeiGene. It has been approved in China for the treatment of BRCA recurrent advanced ovarian, fallopian tube or primary peritoneal cancer.
no Declined.[note 8]


___________

  1. ^ This information was moved to the infobox.
  2. ^ This part of the request stated that certain references nearby 'did not validate the source', but the request did not state whether those references should also be removed. Please specify.
  3. ^ Describing the company's recruitment drives is not the purpose of the article.
  4. WP:NOTDIRECTORY
    .    )
  5. ^ It's not clear what is meant by the phrase "collaboration agreement."
  6. WP:NOBLECAUSE
    .
  7. ^ It's not clear from this direction which third paragraph is being referred to.
  8. WP:COATRACK
    .    )

Thank you as always for your feedback! A few specific responses:
  • Note 2: The references in question do not need to be removed; they're substantiating the following sentence, "Wang and Oyler envisioned a biopharmaceutical company with research and development in China, focusing on cancer treatment."
  • Note 3: Understood, but this request was to update content already in the article ("By July 2011, they had recruited more than 60 Chinese scientists, including 20 who were U.S.-educated."). If it's out of scope, do we want to delete it rather than updating it?
  • Note 5: Updated with more specific wording:
In November 2018, BeiGene began a license and collaboration agreement with biotech company Zymeworks, giving BeiGene the rights to two drugs in certain markets and allowing BeiGene and Zymeworks to share research and development data.[1] In December 2021, the two companies began a phase 3 clinical trial of zanidatamab, a bispecific antibody.[2]
  • Note 7: This is for the third paragraph of the "Research and development" section, at the end of the paragraph on zanubrutinib.
  • Finally, any thoughts on my request to capitalize the G in the article title and throughout the body, per the majority of media coverage and
    MOS:CAMELCASE
    ?
Sources

  1. ^ Taylor, Nick Paul (27 November 2018). "BeiGene bags Asian rights to Zymeworks' HER2 bispecifics". Fierce Biotech. Retrieved 30 June 2023.
  2. ^ Buntz, Brian (9 December 2021). "Zymeworks and its partner BeiGene expand zanidatamab pivotal trial in Asia". Drug Discovery and Development. Retrieved 30 June 2023.
Thanks again. Mary Gaulke (talk) 21:02, 18 July 2023 (UTC)[reply]
Hi @Spintendo:! I neglected to ping you on the above so doing so now. Thank you! Mary Gaulke (talk) 13:56, 25 July 2023 (UTC)[reply]
Thank you for your reply.
  1. The references in question do not need to be removed; they're substantiating the following sentence If the references do not need to be removed because they are already substantiating a nearby claim (and by "nearby" you mean
    WP:INTEGRITY
    is being followed) then no change needs to be made (because they're already properly substantiating that claim). If they are improperly substantiating a nearby claim because integrity is not being followed, then that needs to be specified in the request along with information on where to move the old/new references so that they substantiate the right claims. If the references are updating older references which are no longer correct, then the older references need to be included in the request so that they can be identified and removed from the article.
  2. If it's out of scope, do we want to delete it rather than updating it? That's the goal, but that deletion should ideally come in the form of a new request.
  3. at the end of the paragraph on zanubrutinib Is zanubrutinib Wikilinked? If the information is about the drug, then it should be placed on the drug's page and not on the page about the company.
  4. Updated with more specific wording: In November 2018, BeiGene began a license and collaboration agreement with biotech company Zymeworks "Collaboration agreements" could mean anything, and beyond that seems to be just everyday information about the company's actions that is not really relevant to the article. If the company comes to an agreement with a certain phone service provider to handle its telephone calls or if the company enters into an agreement with a janitorial service to handle the cleaning of its buildings, those agreements, though extreme as examples, are just normal collaboration agreements that keep the company in business. If 10 years from now that collaboration agreement ended up producing a blockbuster drug which made major news around the world, then it would be relevant to include the information about that collaboration agreement in the article at that time. Regards,  Spintendo  05:08, 5 August 2023 (UTC)[reply]
@Spintendo: Hello!
1. To be clear, I'm requesting that
While many pharmaceutical drugs are manufactured in China, almost all early research and development for the drugs takes place elsewhere. Wang and Oyler envisioned a biopharmaceutical company with research and development in China, focusing on cancer treatment.[1][2]
be updated to
Wang and Oyler envisioned a biopharmaceutical company with research and development in China, focusing on cancer treatment.[1][3]
The sources verify the second sentence, but not the first. Hence, I believe it makes sense to delete the first sentence while retaining the second sentence and its sources.
Sources

  1. ^ a b Cite error: The named reference :0 was invoked but never defined (see the help page).
  2. ^ Wright, Rob (2019-11-01). "How — And Why — John Oyler Built BeiGene". Life Science Leader. Retrieved 2020-08-04.
  3. ^ Wright, Rob (2019-11-01). "How — And Why — John Oyler Built BeiGene". Life Science Leader. Retrieved 2020-08-04.
All the rest makes sense, and I can open up a new request for item 2. I'd also welcome any feedback you have on how I can address the {{Advert}} tag and the {{Excessive citations}} tag you placed. Is the latter as simple as reviewing any locations where there are three citations and choosing one to remove? Thanks! Mary Gaulke (talk) 19:14, 7 August 2023 (UTC)[reply]
@MaryGaulke Thank you for your reply. The way you explained the first claim, about the drugs being manufactured in China, that makes much more sense now. I can remove the first part of those sentence. As far as the too many citations maintenance template, ideally, if one reference can cover a claim, then additional references are not necessary. The article should be combed to make sure that there are no duplicate references, meaning, there should not be two different sources confirming the exact same information. (I count 14 instances where two or more references stand side by side in the article, apparently referencing the same information. These should be checked to make sure they're not actually referencing different parts of the same sentence or sentences, in which case they should be moved to their proper positions.) I can't speak to the advert maintenance template, since I had nothing to do with its emplacement. Regards,  Spintendo  19:18, 15 August 2023 (UTC) and inserted text 20:02, 15 August 2023 (UTC)[reply]
Sounds great. Thanks for your help! Mary Gaulke (talk) 19:34, 15 August 2023 (UTC)[reply]
I would add that I typically ask COI editors to speak with the editor who placed the template to see if it can be removed, and if they don't receive a response then I'll take a look at it. Regards,  Spintendo  19:39, 15 August 2023 (UTC)[reply]
Roger that! I've reached out to the editor who placed the template. Thanks again. Mary Gaulke (talk) 19:49, 15 August 2023 (UTC)[reply]
Hi! Confirming it's been a week since I reached out to the editor who placed the template. While the editor has been active during that time, they have not replied to me, so I'm guessing they no longer wish to be involved. Any feedback you could share on addressing the advert flag would be most appreciated. Mary Gaulke (talk) 15:12, 22 August 2023 (UTC)[reply]

COI edit requests v.2

Hi again! As noted above, I'm a COI editor for BeiGene, opening up a new request for a few outstanding/new items per the discussion above.

1. Update the {{Short description}} to "Global biotechnology company", per the article lead.
2. In the infobox, please update the number of employees to 10,000[1]
3. In the second paragraph of "History", delete per the above discussion:
By July 2011, they had recruited more than 60 Chinese scientists, including 20 who were U.S.-educated.
Alternatively, this could be updated as follows, per the cited source:[2]
By July 2011, they had recruited 60 scientists, including 20 who were Chinese-born and U.S.-educated or had worked at an American or European pharmaceutical company.
4. To address {{excessive citations}}:
  • Delete the second ref after "Wang and Oyler envisioned a biopharmaceutical company focusing on cancer treatment, with research and development both taking place in China.[2][3]" – The first ref is sufficient to confirm the information.
  • Delete the first ref[4] after "In a March 2018 follow-on offering, BeiGene raised another $758 million.[4][5]" – The second ref confirms the information.
  • Delete the second ref after "In August 2018, the company had another IPO when it offered a secondary listing of its shares on the Hong Kong Stock Exchange, raising $903 million in the process.[6][7]"
  • Update
In July 2017, BeiGene entered into a partnership with Celgene to continue the development and commercialization of the cancer drug BGB-A317, also known as tislelizumab.[8][9]
to
In July 2017, BeiGene entered into a partnership with Celgene to continue the development and commercialization of the cancer drug BGB-A317,[9] also known as tislelizumab.[8]
  • After "BeiGene also acquired Celgene's operations in China as well as the rights to commercialize Abraxane, Revlimid and Vidaza, Celgene's approved drugs in China.", add this ref: [10] (This is actually a sentence that was missing a ref, so I found one.)
  • Delete the first ref after "As part of the deal, Celgene made a $150 million equity investment in BeiGene and acquired the rights for the sale of tislelizumab overseas for $263 million, with another $980 million plus royalties contingent on future sales.[11][12]"
  • Delete the second and third refs after "In 2019, Amgen Inc. acquired 20.5% of BeiGene in a deal valued at $2.7 billion, and gained a seat on BeiGene's board of directors. In turn, BeiGene acquired the rights to commercialize three Amgen pharmaceuticals, Xgeva, Kyprolis, and Blincyto, as well as 20 others in development, investing $1.25 billion toward their research.[13][14][15]"
  • Delete the second ref after "In January 2021, BeiGene announced a collaboration and license agreement with Novartis to develop and commercialize tislelizumab in Canada, member countries of the European Union, Switzerland, Iceland, Japan, Liechtenstein, Mexico, Norway, Russia, United Kingdom, and the U.S.[16][17]"
  • Delete the second ref after "In May 2021, BeiGene and Asieris Pharmaceuticals worked together to assess the efficacy and quality of Asieris's MetAP2 inhibitor and BeiGene's PD-L1 inhibitor for bladder cancer patients.[18][19]"
  • Delete the first and second refs after "Tislelizumab is being developed as a monotherapy and for use in combination with other therapies for several types of cancer.[20][21][22]"
  • Delete the second ref after "In September 2021, the U.S.
    esophageal squamous cell carcinoma that has previously been treated with systemic therapy.[23][24]
    "
  • Delete the second ref after "BeiGene also developed zanubrutinib, a Bruton's tyrosine kinase inhibitor for the treatment of cancer, from a formula its scientists created in Beijing in 2012.[8][25]"
  • Update
In November 2019, zanubrutinib became the first cancer drug developed in China to gain FDA approval; it received accelerated approval for the treatment of mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.[26][27]
to
In November 2019, zanubrutinib became the first cancer drug developed in China to gain FDA approval;[28] it received accelerated approval for the treatment of mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.[29]
Sources

  1. ^ "Form 10-Q". BeiGene. 30 June 2023. Retrieved 15 August 2023.
  2. ^ a b Loo, Daryl (2011-07-07). "BeiGene Brings Biotech to China". Bloomberg. Retrieved 2020-08-04.
  3. ^ Wright, Rob (2019-11-01). "How — And Why — John Oyler Built BeiGene". Life Science Leader. Retrieved 2020-08-04.
  4. ^
    ISSN 0362-4331
    . Retrieved 2020-08-04.
  5. ^ Micklus, Amanda (2018-03-14). "Deals In Depth: January 2018". In Vivo. Informa. Retrieved 2020-08-04.
  6. ^ Lau, Fiona; Zhu, Julie (2018-08-02). "Chinese biotech BeiGene raises $903 million in HK's first secondary listing under new rules: sources". Reuters. Retrieved 2020-08-04.
  7. ^ Mukherjee, Sy (2019-11-14). "China Biotech BeiGene Wins FDA Approval for Rare Blood Cancer Drug". Fortune. Retrieved 2020-08-04.
  8. ^ a b c Robbins, Rebecca (2019-02-13). "For BeiGene, Bristol-Celgene deal is poised to have big ripple effects". STAT. Retrieved 2020-08-04.
  9. ^ a b Grover, Divya; Pratap, Bhanu (2017-07-05). "Celgene signs deal with BeiGene for tumor cancer treatment". Reuters. Retrieved 2020-08-04.
  10. ^ Taylor, Nick Paul (6 July 2017). "Celgene bags Beigene PD-1 drug for $263M up front". Fierce Biotech. Retrieved 16 August 2023.
  11. ^ Hancock, Tom; Xueqiao, Wang (2017-11-23). "Investors place bet on Chinese drugmakers". Financial Times. Retrieved 2020-08-04.
  12. ^ Feuerstein, Adam (2017-07-06). "Celgene now owns a checkpoint inhibitor for solid tumors, but is Beigene deal too late for cancer immunotherapy race?". STAT. Retrieved 2020-08-04.
  13. ^ Armstrong, Drew; Lyu, Dong (2019-10-31). "Amgen to Take $2.7 Billion Stake in BeiGene for China Growth". Bloomberg. Retrieved 2020-08-04.
  14. ^ Beasley, Deena (2019-10-31). "Amgen takes 20.5% stake in BeiGene to sell cancer drugs in China". Reuters. Retrieved 2020-08-04.
  15. ISSN 0099-9660
    . Retrieved 2020-08-04.
  16. ^ "Novartis Licenses BeiGene's Anti-PD-1 Agent Tislelizumab in North America, Europe, Japan". Precision Oncology News. 2021-02-26. Retrieved 2021-06-21.
  17. ^ "Novartis lays out $650M-plus for BeiGene's tislelizumab as its own PD-1 fails to impress". FiercePharma. Retrieved 2021-06-21.
  18. ^ "Asieris and BeiGene to Test Combination Therapy for Bladder Cancer". Chinabio Today. 6 May 2021. Archived from the original on 2021-05-10. Retrieved 7 May 2021.
  19. ^ Khan, Tuba (7 May 2021). "BeiGene and Asieris Enter into Clinical Collaboration for APL-1202 + Tislelizumab to Treat Muscle Invasive Bladder Cancer". PharmaShots. Archived from the original on 2021-05-07. Retrieved 7 May 2021.
  20. ISSN 0099-9660
    . Retrieved 2020-08-05.
  21. PMID 30516432
    .
  22. PMID 32540858
    .
  23. ^ Park, Brian (2021-09-13). "Tislelizumab Under Review for Esophageal Squamous Cell Carcinoma". MPR. Archived from the original on 2021-09-13. Retrieved 2021-12-08.
  24. ^ Rosa, Kristi (September 13, 2021). "FDA Accepts BLA for Tislelizumab in Esophageal Squamous Cell Carcinoma". OncLive. Archived from the original on 2021-09-14. Retrieved 2021-12-08.
  25. PMID 30679329
    .
  26. ^ "FDA Approves First Chinese Cancer Drug for U.S. Patient Use". Bloomberg. 2019-11-15. Retrieved 2020-08-05.
  27. ^ Mathias, Tamara; Maddipatla, Manojna (2019-11-14). "China's BeiGene gets FDA approval for drug to treat rare form of lymphoma". Reuters. Retrieved 2020-08-05.
  28. ^ "FDA Approves First Chinese Cancer Drug for U.S. Patient Use". Bloomberg. 2019-11-15. Retrieved 2020-08-05.
  29. ^ Mathias, Tamara; Maddipatla, Manojna (2019-11-14). "China's BeiGene gets FDA approval for drug to treat rare form of lymphoma". Reuters. Retrieved 2020-08-05.
  30. ^ Dylann, Cohn-Emery (September 1, 2021). "FDA Approves Zanubrutinib in Adult Waldenström's Macroglobulinemia". Targeted Oncology. Archived from the original on 2021-09-01. Retrieved 2021-12-08.
  31. ^ Mulcahy, Nick (September 2, 2021). "FDA Approval for Zanubrutinib in Waldenström's Macroglobulinemia". Medscape. Archived from the original on 2021-09-02. Retrieved 2021-12-08.
  32. ^ "FDA approves Brukinsa for advanced marginal zone lymphoma". Healio. September 15, 2021. Archived from the original on 2021-09-15. Retrieved 2021-12-08.
  33. ^ Park, Brian (September 15, 2021). "Brukinsa Gets Accelerated Approval for Marginal Zone Lymphoma". MPR. Retrieved 2021-12-08.

Thank you for your time and support! Mary Gaulke (talk) 17:06, 16 August 2023 (UTC)[reply]

Approved and implemented.  Spintendo  17:51, 17 August 2023 (UTC)[reply]

COI edit requests for lead, History, Research and development

Hi! As noted above, I'm a COI editor for BeiGene. I'm hoping to build out this article a little more to reflect the structure and depth of information in comparable articles like Vertex Pharmaceuticals, BioNTech, and Biogen. Here's what I suggest:

  • In the lead, update
including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
to
including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor.
For the symmetry of providing a brief description of each, rather than only tislelizumab.
  • Add to end of "History":
As of 2023, the company was constructing a $700 million investment site for biologics manufacturing and research and development. Located in Hopewell, New Jersey, it is scheduled to open in 2024.[1]
  • I think it makes sense to move the last two paragraphs of "Research and development" into a new "Products" or "Medicines" section. Each paragraph could also be a subsection: "Tislelizumab" and "Zanubrutinib".
  • In the paragraph on zanubrutinib, update
In June 2020, the drug was also approved in China for the treatment of MCL, chronic lymphocytic leukemia, and small lymphocytic lymphoma.[2]
to
In June 2020, the drug was also approved in China for the treatment of MCL, chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL);[3] it was then approved for the treatment of CLL[4] and SLL by the European Commission in November 2022[5] and by the FDA in January 2023.[6]
N.B. This is similar to a request I previously proposed that was rejected above. I've adjusted the request to appear adjacent to related information in the article (the Chinese approval of the drug for the same indications). If this information is not appropriate for this article, I suggest the sentence be removed entirely; listing only the Chinese approval when it is also approved in the US and EU seems unnecessarily confusing.
  • Add to the end of "Research and development":
From 2019 to 2022, BeiGene's internal research team of preclinical scientists grew from 200 to more than 800 people.[7] In 2022, BeiGene became the only pharmaceutical company in China to have invested more than 10 billion yuan ($145 billion) in research and development. As of 2023, the company had approximately 50 clinical candidates or products in development or in the commercialization process.[8]


Sources

  1. ^ Flannery, Russell (22 March 2023). "BeiGene Expects To Finish Construction At $700 Million New Jersey Site In 2024". Forbes. Retrieved 22 August 2023.
  2. ^ Columbus, Gina (2020-06-03). "Zanubrutinib Gains Approval in China for Relapsed/Refractory CLL/SLL and MCL". OncLive. Retrieved 2020-08-05.
  3. ^ Columbus, Gina (2020-06-03). "Zanubrutinib Gains Approval in China for Relapsed/Refractory CLL/SLL and MCL". OncLive. Retrieved 2020-08-05.
  4. ^ "BeiGene's Brukinsa receives EC approval for chronic lymphocytic leukaemia". PMLive. 21 November 2022. Retrieved 30 June 2023.
  5. ^ Liu, Angus (22 November 2022). "ASH: AbbVie, J&J's Imbruvica under serious threat as BeiGene's Brukinsa delivers head-to-head trial win". Fierce Pharma. Retrieved 30 June 2023.
  6. ^ Killmurray, Conor (19 January 2023). "FDA Approves Zanubrutinib in Adult Patients with CLL/SLL". Targeted Oncology. Retrieved 30 June 2023.
  7. ^ Liu, Simu (6 July 2022). "BeiGene's R&D chief knows PD-1 is crowded. But TIGIT, combos and a Novartis partnership put asset in play". Fierce Biotech. Retrieved 23 August 2023.
  8. ^ Si, Ellie (11 May 2023). "BeiGene Goes For Global Growth With Sales And R&D Push". Seeking Alpha. Retrieved 23 August 2023.

Thank you for your time and feedback! Mary Gaulke (talk) 19:00, 11 September 2023 (UTC)[reply]

Reply 12-SEP-2023

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.  Spintendo  00:46, 13 September 2023 (UTC)[reply]

Edit request review 12-SEP-2023

including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


As of 2023, the company was constructing a $700 million investment site for biologics manufacturing and research and development. Located in Hopewell, New Jersey, it is scheduled to open in 2024.
no Declined.[note 1]


In June 2020, the drug was also approved in China for the treatment of MCL, chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL); it was then approved for the treatment of CLL and SLL by the European Commission in November 2022 and by the FDA in January 2023.
Clarification needed.[note 2]


From 2019 to 2022, BeiGene's internal research team of preclinical scientists grew from 200 to more than 800 people. In 2022, BeiGene became the only pharmaceutical company in China to have invested more than 10 billion yuan ($145 billion) in research and development. As of 2023, the company had approximately 50 clinical candidates or products in development or in the commercialization process.
no Declined.[note 3]


___________

  1. WP:CRYSTALBALL
    .    )
  2. ^ It does not state for what reason the FDA approved its use for. As the other statements in this section all give reason for its use, omitting the FDA's reasons stands out, and should be addressed.
  3. ^ I'm not comfortable adding this information based on the references provided. Firstly, the growth of BeiGene's "internal research team of preclinical scientists" could mean anything, and is not illuminating enough as information. Secondly, having "50 clinical candidates in production or development" is also not very illuminating. So are these actually in production, development, or undergoing the "commercialization process"? The proposed statement does not delineate.

revised COI edit requests for lead, History, Research and development

Hello! Sharing revised versions of my edit requests above per the feedback received.

  • Add to end of "History":
As of 2023, the company was constructing a $700 million investment site in Hopewell, New Jersey, for biologics manufacturing and research and development.[1]
  • Split the last two paragraphs of "Research and development" into a new section titled "Medicines" or "Products".
  • In the paragraph on zanubrutinib (currently in "Research and development"), update
In June 2020, the drug was also approved in China for the treatment of MCL, chronic lymphocytic leukemia, and small lymphocytic lymphoma.[2]
to
In June 2020, the drug was also approved in China for the treatment of MCL, chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL);[3] it was then approved for the treatment of CLL[4] and SLL by the European Commission in November 2022[5] and by the FDA for the same indications in January 2023.[6]

References

  1. ^ Flannery, Russell (22 March 2023). "BeiGene Expects To Finish Construction At $700 Million New Jersey Site In 2024". Forbes. Retrieved 22 August 2023.
  2. ^ Columbus, Gina (2020-06-03). "Zanubrutinib Gains Approval in China for Relapsed/Refractory CLL/SLL and MCL". OncLive. Retrieved 2020-08-05.
  3. ^ Columbus, Gina (2020-06-03). "Zanubrutinib Gains Approval in China for Relapsed/Refractory CLL/SLL and MCL". OncLive. Retrieved 2020-08-05.
  4. ^ "BeiGene's Brukinsa receives EC approval for chronic lymphocytic leukaemia". PMLive. 21 November 2022. Retrieved 30 June 2023.
  5. ^ Liu, Angus (22 November 2022). "ASH: AbbVie, J&J's Imbruvica under serious threat as BeiGene's Brukinsa delivers head-to-head trial win". Fierce Pharma. Retrieved 30 June 2023.
  6. ^ Killmurray, Conor (19 January 2023). "FDA Approves Zanubrutinib in Adult Patients with CLL/SLL". Targeted Oncology. Retrieved 30 June 2023.

Thanks for your time! Mary Gaulke (talk) 13:55, 18 October 2023 (UTC)[reply]

Reply 18-OCT-2023

✅  Edit request partially implemented  

  1. Red XN The information concerning the Hopewell site was not added, for the same reason given in the reply from 12-SEP-2023 (i.e., the company was constructing as opposed to constructed meaning finished).
  2. Green tickY The paragraph on zanubrutinib was updated.
  3. Red XN The last two paragraphs were not split under a new heading because the suggested level of that heading (i.e., 2 or 3) was not provided with the request.

Regards,  Spintendo  02:18, 19 October 2023 (UTC)[reply]

Nov. 2023 COI edit request

Hi! COI editor for BeiGene here with a few new requests.

  • In the final paragraph of "History", add before "In May 2021,":
Novartis returned the rights to tislelizumab to BeiGene in September 2023.[1]
(I'm suggesting this placement as it follows a previous sentence on the Novartis agreement.)
  • Split the last two paragraphs of "Research and development" into a new level-2 section titled "Medicines" or "Products".
  • Add after the first paragraph of "Research and development":
In the years since, BeiGene has shifted toward an integrated approach to research and development, investing in in-house clinical development and trials rather than partnering with contract research organizations to run trials.[2] The company has built up the capacity to run clinical trials in several regions simultaneously,[3] providing larger numbers of patients with more diversity. According to BeiGene, this approach has reduced trial costs by 30% and reduced the time trials take.[2] As of 2022, BeiGene had trial sites in 45 countries.[4]
BeiGene has favored head-to-head clinical trials to validate the benefits of medicines,[3] including two large global phase 3 clinical trials comparing zanubrutinib to ibrutinib between 2017 and 2023.[2] In 2022, BeiGene became the only pharmaceutical company in China to have invested more than 10 billion yuan ($145 billion) in research and development.[5]
  • Finally, could the {{advert}} flag be removed from this article? I reached out to the editor who placed the template a few months ago for feedback on how to address it and haven't heard back. I also welcome any feedback on how I can help with addressing the advert flag.

References

  1. ^ Bonanos, Paul (19 September 2023). "As Novartis PD-1 deal ends, BeiGene sees U.S., EU as gateways to global access". BioCentury. Retrieved 27 November 2023.
  2. ^ a b c Zhang Liang (11 September 2023). "抗癌新势力：百济神州的颠覆与创新". Harvard Business Review China. Retrieved 27 November 2023.
  3. ^ a b Henderson, Lisa (29 March 2023). "A Vision of Affordability". PharmExec. Retrieved 14 September 2023.
  4. ^ Flannery, Russell (11 August 2022). "Curing Cancer Takes A Global Village: Cancer Moonshot Pathways". Forbes. Retrieved 14 September 2023.
  5. ^ Si, Ellie (11 May 2023). "BeiGene Goes For Global Growth With Sales And R&D Push". Seeking Alpha. Retrieved 23 August 2023.

Thank you for your help! Mary Gaulke (talk) 21:38, 30 November 2023 (UTC)[reply]

Reply 30-NOV-2023

✅  Edit request partially implemented  

  1. Green tickY The information regarding Novartis was added.
  2. Red XN The information regarding contract research organizations was not added, because other information in the article already covers this change in business models (In addition to clinical research, BeiGene's early business model involved obtaining the rights to experimental medicines shelved by other pharmaceutical companies and taking them through early clinical trials at Chinese medical schools and hospitals. Successful formulas would either be sold to or co-developed with larger drugmakers who could fund the late-stage trials.
  3. Red XN The infomration regarding Beigene's reduction in trial costs was not added. It is not Wikipedia's duty to tell the world that Beigene is saving money.
  4. Red XN The information concerning the phase 3 trials was not added, as what Beigene favors or does not favor is not Wikipedia's concern. Additionally, the claim of being the "only pharmaceutical company" cannot be substantiated with only one provided reference.
  • Please provide diffs of your efforts to reach out to the editor who posted the maintenance message.

Regards,  Spintendo  03:29, 1 December 2023 (UTC)[reply]

@Spintendo: Hi! Here's the diff where I reached out to the editor who posted the maintenance message. Thanks! Mary Gaulke (talk) 22:42, 12 December 2023 (UTC)[reply]
Thank you for providing this. I've reached out to the editor as well. By the looks of their contributions, they are quite busy, so it's understandable if they were unable to get back to us. I reiterated that we value their input, and if they wished so in the future we would be happy to have them join in our discussion with any comments/concerns. In the meantime, I've removed the template, since we cannot know for certain if the conditions which they felt caused its placement are still in the article or have been resolved. Regards,  Spintendo  04:38, 14 December 2023 (UTC)[reply]

March 2024 COI edit requests

Hi! COI editor for BeiGene here again with a couple new requests:

  • In infobox, update
| num_employees = 10,000
to
| num_employees = 10,600[1]
| num_employees_year = 2024
  • Add to end of "History":
In 2023, BeiGene saw a 75% increase in product sales to $2.2 billion, primarily due to sales of Brukinsa (zanubrutinib), which more than doubled 2022 sales and attained blockbuster drug status with $1.3 billion in sales.[1]

References

  1. ^ a b Liu, Angus (26 February 2024). "BeiGene grows global workforce by 1,000-plus as Brukinsa surges, Tevimbra launches outside China". Fierce Pharma. Retrieved 5 March 2024.

Thanks for your help! Mary Gaulke (talk) 18:14, 5 March 2024 (UTC)[reply]

Hello there!
I'm happy to admit I'm a newer wiki editor! But, I have mostly been into IBX field stuff.
As such, I'm happy to add your proposed IBX changes via the citation.
"
| num_employees = 10,000
to
| num_employees = 10,600
| num_employees_year = 2024
However, I am not as yet well versed in the protocol for the actual article bodies and their cites/phrasings.
We all start somewhere, right, maybe? If you're happy to (not sure of that protocol here as well) possibly: re-request the latter half of your request for a more seasoned editor to review...
I also can't argue against it, so if my full-agreement, half-contribution is not helpful, please let me know!
I'll shut up.
I'm learning!
Thanks! Dunkinidaho (talk) 06:24, 24 March 2024 (UTC)[reply]
Hello there again, @MaryGaulke!
I've refreshed my article-body notability & RS chops... and as it turns out, I'd be happy to add your edit AS suggested, and (checking back here in a couple days) will proceed to do so-- barring no fellow editor pushback between.
Along with the IBX update for '24,I find it "well sourced*, neutral, and follows other Wikipedia guidelines and policies.
Thanks again,
d-id
(*I think the actual beigene-hosted SEC filing (cited specifically for the IBX info update) in tandem to the one you provided (and cited in the sentence added to "History") would speak to the verifiability of the claim in the cited RS, that itself cites the official fed filing. But I think if anything this is overkill, and just more links on wikipedia, actually?) Dunkinidaho (talk) 06:18, 25 March 2024 (UTC)[reply]
@Dunkinidaho: Thanks for your help! I believe the same re: the SEC filing – I believe primary source isn't necessary given the secondary source cites it. Mary Gaulke (talk) 20:14, 25 March 2024 (UTC)[reply]

Conflict of interest edits

I believe this article is being edited by editors who have a conflict of interest and/or are being paid. In particular, several new accounts have been created minutes before their first edit, and have made several edits to this article, and no other article. Seeing this talk page, this company obviously has a lot of interest in keeping this page how they want it, and so they put in a lot of COI edit requests. Unfortunately it seems some edits are happening that are not going through this proper channel. I'm going to post to the

noticeboard
if I get no response.

@Nyg58: @Kablankblank: @Nkmillsmedia: @Mtpmedia: @Crileymiller: @UofMMedia: Kimen8 (talk) 01:20, 28 March 2024 (UTC)[reply]

Several of these editors have received blocks due to their username violating the username policy. In particular, they are Groups that are being paid to edit this article. Since there are so many paid contributions in such a short span of time, I have annotated the article with appropriate templates. This is egregious. I want to expand the list to also include:
I have created a post to the noticeboard here.
Kimen8 (talk) 13:46, 31 March 2024 (UTC)[reply]

@MaryGaulke: given your role as (appropriately; thank you) declared above, are you aware of this? Andy Mabbett (Pigsonthewing); Talk to Andy; Andy's edits 15:40, 31 March 2024 (UTC)[reply]

@
WP:OUTING is a concern. I can confirm I advised my client on Wikipedia's COI disclosure policies. Mary Gaulke (talk) 16:30, 31 March 2024 (UTC)[reply
]
Thank you; that's clear enough. Andy Mabbett (Pigsonthewing); Talk to Andy; Andy's edits 16:38, 31 March 2024 (UTC)[reply]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:BeiGene&oldid=1216542286"